Vivace Therapeutics Stock
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Sign up today and learn more about Vivace Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vivace Therapeutics Stock
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.
Funding History
January 2015 | $15.0M |
---|---|
June 2017 | $25.0M |
December 2020 | $30.0M |
Management
President and Chief Executive Officer
Sofie Qiao
Board Member
Dr. Norman Zhou
Director Of Operations
Amy Pfeiffer
Chief Scientific Officer
Leonard Post
Vice President of Corporate Development
Tuomas Holmberg
Vice President of Biology of Vivace Therapeutics
Tracy Tang
Vice President of Chemistry
Andrei Konradi
Press
aacrjournals - Dec, 21 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and ...prnewswire - Dec, 21 2023
Neurofibromatosis Type 2 Market to Observe Impressive ...medgadget - Dec, 21 2023
Neuroendocrine Tumors Clinical Trial Pipeline Insights | 55+ ...bioworld - Nov, 19 2023
Vivace Therapeutics divulges new YAP1/TEAD and TAZ/TEAD interaction inhibitorsbioworld - Aug, 25 2023
Vivace Therapeutics describes new YAP1/TEAD interaction inhibitors